Skip to Main Content

Author Details

Martha Nowosielski
Medical University of Innsbruck
2009
44
22
Nathan Sheffield (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36900177Peritumoral ADC Values Correlate with the MGMT Methylation Status in Patients with Glioblastoma.Cancers (Basel)2023
37707754Somatostatin receptor subtype expression and radiomics from DWI-MRI represent SUV of [68Ga]Ga-DOTATOC PET in patients with meningioma.J Neurooncol2023
37738478Towards more Diversity in Neuro-oncology Leadership-the DivINe Initiative.Neuro Oncol2023
35267049Whole brain radiotherapy combined with intrathecal liposomal cytarabine for leptomeningeal metastasis-a safety analysis and validation of the EANO-ESMO classification.Strahlenther Onkol2022
35394585ADC textural features in patients with single brain metastases improve clinical risk models.Clin Exp Metastasis2022
36216458Prevention of Oxidative Damage in Spinal Cord Ischemia Upon Aortic Surgery: First-In-Human Results of Shock Wave Therapy Prove Safety and Feasibility.J Am Heart Assoc2022
35326730MRI Response Assessment in Glioblastoma Patients Treated with Dendritic-Cell-Based Immunotherapy.Cancers (Basel)2022
34799551Bilateral medial medullary syndrome following anterior screw fixation of type 2 odontoid fracture, a case report of two patients.Spinal Cord Ser Cases2021
33706200Perampanel in brain tumor and SMART-syndrome related epilepsy - A single institutional experience.J Neurol Sci2021
34940063Changes in Brain Energy and Membrane Metabolism in Glioblastoma following Chemoradiation.Curr Oncol2021
32393964Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.Neuro Oncol2020
32720870Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial.Radiology2020
32461353Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors.Neurol Neuroimmunol Neuroinflamm2020
30365968Evaluating cellularity and structural connectivity on whole brain slides using a custom-made digital pathology pipeline.J Neurosci Methods2019
31369680Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial.Neuro Oncol2019
30952559Automated quantitative tumour response assessment of MRI in neuro-oncology with artificial neural networks: a multicentre, retrospective study.Lancet Oncol2019
31076534Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study.Neurology2019
29016943Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.Neuro Oncol2018
30150718The DNA methylation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space.Nat Med2018
30301187Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial.Cancers (Basel)2018
29548049Imaging Criteria in Neuro-oncology.Semin Neurol2018
28531331Diagnostic challenges in meningioma.Neuro Oncol2017
27298312Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.Neuro Oncol2016
26578622Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas.Neuro Oncol2016
27677656How to facilitate early diagnosis of CNS involvement in malignant lymphoma.Expert Rev Hematol2016
27636026Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features.Radiology2016
27803067Large-scale Radiomic Profiling of Recurrent Glioblastoma Identifies an Imaging Predictor for Stratifying Anti-Angiogenic Treatment Response.Clin Cancer Res2016
25038253Pseudoprogression in patients with glioblastoma: clinical relevance despite low incidence.Neuro Oncol2015
26254394Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment.Anticancer Res2015
26112809The emerging role of advanced neuroimaging techniques for brain metastases.Chin Clin Oncol2015
25789657Nuclear Overhauser Enhancement imaging of glioblastoma at 7 Tesla: region specific correlation with apparent diffusion coefficient and histology.PLoS One2015
25754089Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.Neuro Oncol2015
24220008Polyarteritis nodosa complicating multiple myeloma - a case report and review of the literature.Clin Neuropathol2014
25415327Quantification of tumor vessels in glioblastoma patients using time-of-flight angiography at 7 Tesla: a feasibility study.PLoS One2014
24759867An intra-individual comparison of MRI, [18F]-FET and [18F]-FLT PET in patients with high-grade gliomas.PLoS One2014
24727314Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma.Neurology2014
24311637A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).Neuro Oncol2014
23335162[18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma.Neuro Oncol2013
23788269Response to "reply to [18F]-fluoro-ethyl-L-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma" by Hutterer et al.Neuro Oncol2013
19896736Predictive value of NT-pro BNP after acute myocardial infarction: relation with acute and chronic infarct size and myocardial function.Int J Cardiol2011
21622893O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.J Nucl Med2011
21125399ADC histograms predict response to anti-angiogenic therapy in patients with recurrent high-grade glioma.Neuroradiology2011
19161193Quantification of regional functional improvement of infarcted myocardium after primary PTCA by contrast-enhanced magnetic resonance imaging.J Magn Reson Imaging2009
19589148Comparison of wall thickening and ejection fraction by cardiovascular magnetic resonance and echocardiography in acute myocardial infarction.J Cardiovasc Magn Reson2009
  • 1 - 44 of 44

Recommended Authors

Priya Kumthekar
Northwestern University, Feinberg School of Medicine
Career Start Year 2013
Number of shared co-authors 5
Vincent Dunet
Lausanne University Hospital and University of Lausanne
Career Start Year 2011
Number of shared co-authors 0
Vaios Hatzoglou
Memorial Sloan Kettering Cancer Center
Career Start Year 2011
Number of shared co-authors 0
Rohan Ramakrishna
Weill Cornell Medical College, New York Presbyterian Hospital
Career Start Year 2009
Number of shared co-authors 2
Kyrre E Emblem
Oslo University Hospital
Career Start Year 2008
Number of shared co-authors 3
Yoshua Esquenazi
McGovern Medical School at UT Health Houston
Career Start Year 2007
Number of shared co-authors 1
Nancy Ann Oberheim Bush
University of California san francisco
Career Start Year 2005
Number of shared co-authors 3
Nicholas Butowski
University of California san francisco
Career Start Year 2005
Number of shared co-authors 7
Joost J C Verhoeff
University Medical Center Utrecht
Career Start Year 2005
Number of shared co-authors 0
Sherise D Ferguson
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 1
Seung Hong Choi
Seoul National University Hospital
Career Start Year 2003
Number of shared co-authors 0
Thomas J Kaley
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 7
Gelareh Zadeh
University of Toronto
Career Start Year 2003
Number of shared co-authors 11
Marco Skardelly
University Hospital Tubingen, Eberhard-Karls-University Tubingen
Career Start Year 2002
Number of shared co-authors 4
Martin Glas
University Hospital Essen
Career Start Year 2002
Number of shared co-authors 7
Raymond Y Huang
Brigham and Women's Hospital, Harvard Medical School
Career Start Year 2002
Number of shared co-authors 11
Andrew P Morokoff
Clinical Sciences Building, The University of Melbourne, The Royal Melbourne Hospital
Career Start Year 2001
Number of shared co-authors 2
Chul-Kee Park
College of Medicine, Seoul National University
Career Start Year 2000
Number of shared co-authors 5
Ghazaleh Tabatabai
University Hospital Tubingen, Eberhard-Karls-University Tubingen
Career Start Year 1998
Number of shared co-authors 15
Vinay K Puduvalli
The University of Texas MD Anderson Cancer Center
Career Start Year 1996
Number of shared co-authors 4
Tracy T Batchelor
Brigham and Women's Hospital
Career Start Year 1996
Number of shared co-authors 10
Clark C Chen
University of Minnesota
Career Start Year 1994
Number of shared co-authors 2
Ganesh Rao
The University of Texas M.D. Anderson Cancer Center
Career Start Year 1994
Number of shared co-authors 5
Whitney B Pope
David Geffen School of Medicine, University of California los angeles
Career Start Year 1992
Number of shared co-authors 6
Roger Stupp
Northwestern University
Career Start Year 1990
Number of shared co-authors 14
Howard Colman
Huntsman Cancer Institute, University of Utah
Career Start Year 1990
Number of shared co-authors 8
Tom Mikkelsen
Ontario Brain Institute
Career Start Year 1990
Number of shared co-authors 10
Camilo E Fadul
University of Virginia Health System
Career Start Year 1987
Number of shared co-authors 0
Javier E Villanueva-Meyer
University of California san francisco
Career Start Year 1986
Number of shared co-authors 10
Michael A Vogelbaum
Moffit Cancer Center
Career Start Year 1986
Number of shared co-authors 10

Collaborators

G??nther Stockhammer
Medical University of Innsbruck
Co-authored papers 16
Christian F Freyschlag
Medical University of Innsbruck
Co-authored papers 7
Johannes Kerschbaumer
Medical University of Innsbruck
Co-authored papers 7
Felix Sahm
Hopp Children's Cancer Center Heidelberg (KiTZ)
Co-authored papers 6
Benedikt Wiestler
Technical University
Co-authored papers 5
Andreas von Deimling
Co-authored papers 5
Astrid E Grams
Medical University of Innsbruck
Co-authored papers 5
Michael Weller
University Hospital and University of Zurich
Co-authored papers 5
Johanna Buchroithner
Johannes Kepler University
Co-authored papers 4
Stefan Oberndorfer
Karl Landsteiner University of Health Sciences
Co-authored papers 4
Christine Marosi
Medical University of Vienna
Co-authored papers 4
Matthias Preusser
Medical University of Vienna
Co-authored papers 4
Julia Furtner
Medical University of Vienna
Co-authored papers 3
Johannes Haybaeck
Institute of Pathology, Medical University of Innsbruck
Co-authored papers 3
Georg Widhalm
Medical University of Vienna
Co-authored papers 3
Gord von Campe
Medical University of Graz
Co-authored papers 3
Josef Pichler
Kepler University Hospital
Co-authored papers 3
Johannes A Hainfellner
Medical University of Vienna
Co-authored papers 3
Thomas Czech
Co-authored papers 2
Nadine Peter
Institute of Neurology, Medical University of Vienna
Co-authored papers 2
David Capper
Charite University Medicine Berlin
Co-authored papers 2
Claudius Thom??
Medical University Innsbruck
Co-authored papers 2
Marco Augustin
Center for Medical Physics and Biomedical Engineering, Medical University of Vienna
Co-authored papers 2
Adelheid Woehrer
Medical University of Vienna
Co-authored papers 2
Bernhard Baumann
Medical University of Vienna, Center for Medical Physics and Biomedical Engineering
Co-authored papers 2
Thomas Roetzer
Medical University of Vienna
Co-authored papers 2
Eugen Trinka
Christian Doppler University Hospital, Paracelsus Medical University
Co-authored papers 2
Martin Sill
Co-authored papers 2
Warren P Mason
Princess Margaret Cancer Centre
Co-authored papers 1
Tanisa Brandner-Kokalj
Institute of Pathology, State Hospital Klagenfurt
Co-authored papers 1
Release 1.2